# A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

> **NCT04868162** · PHASE2 · RECRUITING · sponsor: **Shanghai Miracogen Inc.** · enrollment: 116 (estimated)

## Conditions studied

- Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** MRG003
- **DRUG:** MRG003+HX008

## Key facts

- **NCT ID:** NCT04868162
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-23
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04868162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04868162, "A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04868162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*